News for Beam Therapeutics Inc. (BEAM)

CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. ( BEAM), a biotechnology company developing precision genetic medicines through base

Wells Fargo's analyst, Yanan Zhu, has adjusted the price target for Beam Therapeutics (BEAM), reducing it from $75 to $70, while maintaining an Overweight ratin

**media[617224]**

Barclays has revised the price target for Beam Therapeutics (BEAM), reducing it from $31 to $25. Despite this adjustment, the firm maintains an Equal Weight rat

Beam Therapeutics Inc's base editing technology positions it as a pioneer in precision genetic medicines.Financial growth reflected by increased cash reserves

Beam Therapeutics (BEAM) stock experienced a notable decline, dropping 19.32% as the market reacted to its recent earnings announcement. The company's latest fi

Beam (BEAM) anticipates that its current financial resources, which include cash, cash equivalents, and marketable securities as of March 31, 2025, along with $

Revenue: $7.47 million, falling short of the estimated $14.87 million.Earnings Per Share (EPS): Reported at -$1.24, slightly below the estimated -$1.21.Cash Po

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -11.71% and 51.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

A significant discussion surrounding advancements in the Alpha-1 Antitrypsin Deficiency (AATD) therapeutic field is set for April 28 at 10 a.m. on an analyst an

U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's ses...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Sana Biotechnology Inc.

Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas.

Ark Invest made major buys in Tempus AI and Coinbase on Thursday, as markets slid amid economic uncertainty and Trump's new 145% China tariffs.

Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Beam Therapeutics Inc (BEAM), a biotechnology company specializing in precision genetic medicines, announced new data from its Phase 1/2 clinical trial of BEAM-

New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3

**media[586704]**

On Friday, April 4, 2025, Cathie Wood-led Ark Invest made substantial trades involving several prominent companies including Coinbase Global Inc. COIN, Amazon.c...